These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24600204)

  • 1. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
    Daikuhara H; Fukunaga K; Ohshima T
    Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
    Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
    Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
    Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
    Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
    Minatoguchi S; Aoyama T; Kawai N; Iwasa M; Oda M; Kida K; Kojima S; Goto N; Goto M; Sugishita F; Takai K; Tanaka R; Hiei K; Minagawa T; Yamamoto N; Watanabe I; Yasue T; Kobayashi H
    Blood Press; 2013 Sep; 22 Suppl 1():29-37. PubMed ID: 23330658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
    Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
    Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
    Kinoshita S; Ryuzaki M; Sone M; Nishida E; Nakamoto H;
    Clin Exp Hypertens; 2014; 36(7):508-16. PubMed ID: 24433108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
    Wang JG; Sun NL; Ke YN; Zhang BH; Ikegami N; Zhu JR
    Clin Drug Investig; 2012 Nov; 32(11):729-34. PubMed ID: 23018282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.
    Sasaki T; Noda Y; Yasuoka Y; Irino H; Abe H; Adachi H; Hattori S; Kitada H; Morisawa D; Miyatake K
    Hypertens Res; 2008 May; 31(5):921-9. PubMed ID: 18712048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST study at 16 weeks.
    Kario K; Saito I; Kushiro T; Teramukai S; Ishikawa Y; Hiramatsu K; Kobayashi F; Shimada K
    J Hum Hypertens; 2013 Dec; 27(12):721-8. PubMed ID: 23863805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
    Vogt L; Navis G; Köster J; Manolis AJ; Reid JL; de Zeeuw D;
    J Hypertens; 2005 Nov; 23(11):2055-61. PubMed ID: 16208149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
    Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
    Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
    Brunner HR; Arakawa K
    Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.